ProCE Banner Activity

CE / CME

Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Text Module

In this module, 5 lung cancer experts review oncology healthcare professional survey results on key educational needs for the multidisciplinary oncology team caring for patients with EGFR-mutated NSCLC, including discussion of standard-of-care practices, the latest clinical data, and ongoing challenges.

Pharmacists: 1.25 contact hours (0.125 CEUs)

Nurses: 1.25 Nursing contact hours

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: September 30, 2022

Expiration: September 29, 2023

No longer available for credit.

Share

Faculty

Edward B. Garon

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Xiuning Le

Xiuning Le, MD, PhD

Assistant Professor
Division of Cancer Medicine
Department of Throracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Mark A. Socinski

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Helena Yu

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Target Audience

This program is intended for physicians, nurses, pharmacists, and other healthcare providers who care for patients with EGFR mutation–positive NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Implement best practices and guideline-endorsed molecular testing algorithms in NSCLC for evaluation of EGFR mutation status in newly diagnosed patients and those with acquired resistance following EGFR TKI therapy
  • Compare available efficacy and safety data of systemic therapies throughout the continuum of EGFR mutation–positive metastatic or locally advanced NSCLC from the first-line setting to the second-line setting and beyond (including outcomes by type of EGFR mutation and the presence of comutations)
  • Describe the biologic rationale for the design of clinical trials combining EGFR-targeted and VEGFR-targeted therapy in EGFR mutation–positive NSCLC and potential ramifications for practice based on recent clinical trial results
  • Plan therapy based on an understanding of the subtype of EGFR mutation as well as comutations such as TP53
  • Refine EGFR mutation–positive metastatic and locally advanced NSCLC treatment algorithms based on molecular profile and prior therapy expsoure in earlier lines of therapy
  • Identify patients eligible to enroll on important ongoing clinical trials evaluating promising investigational agents and combinations for EGFR mutation–positive NSCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Edward B. Garon, MD, MS

Professor
Director of Thoracic Oncology
David Geffen School of Medicine at UCLA
Co-Director of Signal Transduction and Therapeutics Program
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California

Edward B. Garon, MD, MS: consultant/advisor/speaker: ABL Bio, Boehringer Ingelheim, Bristol-Myers Squibb, Dracen, Eisai, EMD Serono, GlaxoSmithKline, Lilly, Merck, Natera, Novartis, Regeneron, Sanofi, Shionogi, Xilio; researcher: ABL Bio, AstraZeneca, Bristol-Myers Squibb, Dynavax Technologies, EMD Serono, Genentech, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, Novartis.

Faculty Disclosure

Primary Author

Xiuning Le, MD, PhD

Assistant Professor
Division of Cancer Medicine
Department of Throracic/Head & Neck Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Xiuning Le, MD, PhD: consultant/advisor/speaker: AstraZeneca, Boehringer Ingelheim, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Lilly, Novartis, Spectrum; researcher: Boehringer Ingelheim, Regeneron.

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD, MHS: researcher (paid to her institution): AbbVie, AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Janssen, Novartis, Spectrum, Takeda, Tesaro; consultant/advisor/speaker: AstraZeneca, Blueprint, C4 Therapeutics, Cullinan Oncology, Genentech, Incyte, Janssen, Jazz, Lilly, Medtronic, Takeda.

Mark A. Socinski, MD

Director, Lung Cancer Section of the Division of Hematology/Oncology
Co-Director, UPMC Center for Excellence in Lung Cancer
Co-Director, Lung and Thoracic Malignancies Program
University of Pittsburgh Cancer Institute
University of Pittsburgh
Pittsburgh, Pennsylvania

Mark A. Socinski, MD, consultant/advisor/speaker: AstraZeneca, BeiGene, G1 Therapeutics, Genentech, Guardant, Janssen, Jazz, Lilly, Regeneron, Takeda, Sanofi; researcher: AstraZeneca, BeiGene, Cullinan, Daiichi Sankyo, Genentech, Novartis, Spectrum, Takeda.

Helena Yu, MD

Associate Attending
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena A. Yu, MD: researcher (paid to her institution): AstraZeneca, Cullinan Oncology, Daiichi Sankyo, Novartis, Pfizer; consultant/advisor/speaker: AstraZeneca, Blueprint Medicine, Daiichi Sankyo, Janssen Oncology.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant financial relationships to disclose.

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.

Jerfiz Constanzo, PhD, MBA

Scientific Director

Jerfiz Constanzo, PhD, MBA, has no relevant financial relationships to disclose.

Jason J. Everly, PharmD

Jason Everly has no relevant financial relationships to disclose.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant financial relationships to disclose.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Jacqueline L. Olin, MS, Pharm.D., BCPS, FASHP, FCC

Jacky Olin, PharmD, has no relevant financial relationships to disclose.

Kristi K. Orbaugh, MSN, RNP, AOCNP

Adult Oncology Nurse Practitioner
Community Hospital Oncology Physician
A Partner of MD Anderson
Indianapolis, Indiana

Kristi Orbaugh has no relevant financial relationships to disclose.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen M. Rosenthal, PharmD, has no relevant financial relationships to disclose.

Jill A. Sakai,

Contributing Editor

Jill Sakai, PhD, has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-231-H01-P.

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 30, 2022, through September 29, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to optimally integrate current data needed to make treatment decisions and improve outcomes in the EGFR mutation–positive NSCLC patient population.